Idazoxan inhibits hyperprolactinaemia in ovariectomized estrogen-treated rats.
The alpha 2-antagonist idazoxan (IDZ) has previously been shown to inhibit hyperprolactinaemia triggered by various stimuli such as lactation, stress, serotonergic agents and morphine (Preziosi, Martire, Navarra, Pistritto and Vacca 1989; Krulich, Jurcovicova and Le 1989). In this study, we investigated the PRL-lowering activity of IDZ in ovariectomized estrogen-treated (OET) rats; since a PRL surge usually occurs in normal cycling rats on the day of proestrus, the effect of IDZ on pulsatile PRL release in intact female rats was also studied. IDZ significantly lowered plasma PRL levels in OET rats; no elevated PRL values were observed in normal cycling rats, indicating that IDZ might inhibit PRL surges in these animals. It is concluded that IDZ is an effective PRL-lowering agent in a number of physiological and pharmacological hyperprolactinaemic models.
Navarra
P
P
Laboratory of Normal and Pathologic Physiology, State University of Ghent, Belgium.
Eechaute
W
W
Preziosi
P
P
Lacroix
E
E
D000818:Animals; D004146:Dioxanes / Q000494:pharmacology / Q000627:therapeutic use*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006966:Hyperprolactinemia / Q000517:prevention & control*; D019329:Idazoxan; D010052:Ovariectomy; D011359:Proestrus; D011388:Prolactin / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains
D004146:Dioxanes; D004958:Estradiol; D011388:Prolactin; C023482:estradiol dipropionate; D019329:Idazoxan